Medtronic (NYSE:MDT) reported positive one-year, real-world clinical data for its MiniMed 780G insulin pump platform in children.
Data came from a subset of 3,211 pediatric and adolescent patients (15 years old and below) with type 1 diabetes using the MiniMed 780G system with the Guardian Sensor 3 in Europe.
Get the full story at our sister site, Drug Delivery Business News.